Navigation Links
Cobalis Corp. Announces Second Update Conference Call for Investors on October 5, 2010
Date:9/28/2010

IRVINE, Calif., Sept. 28 /PRNewswire-FirstCall/ -- Cobalis Corp. (Pink Sheets: CLSC) is holding the second Investor Update Conference Call to provide investors and shareholders with further details and the latest updates about a range of important securities, financial and legal issues.

Shareholders and investors MUST RSVP to participate in this conference call, to be held Tuesday, October 5, 2010 at 1:15pm Pacific Time. Interested parties may RSVP to participate in the call by contacting Cobalis at (949) 260-0123 between 9:00 am and 5:00 pm Pacific Time, Monday through Friday, to get the conference call dial-in number and passcode.

The agenda of this call will include: Financial status and private funding; details of current legal and corporate issues; update on the recent SEC complaint and resolution; resumption of trading; launch update; current legal settlements and how the Company is meeting the terms of its agreements; overview of additional revenue opportunities; what happened with previously planned product release dates.

There will also be a Question and Answer opportunity as well as opportunities following the Conference Call for one-on-one discussions with interested parties.

FORWARD LOOKING STATEMENTS

Cobalis Corp., expectation of results and other forward-looking statements contained in this email involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those expected are the following: business conditions and general economic conditions; competitive factors, such as pricing and marketing efforts; and the pace and success of product research and development. These and other factors may cause expectations to differ.

ABOUT COBALIS CORP—PREHISTIN®

Cobalis Corp. is a specialty pharmaceutical, nutraceutical and preventive healthcare product development and marketing company. Its flagship product, PreHistin® Allergy Defense Formula, The World's FIRST Pre-Histamine, is designed to mitigate overproduction of IgE levels and restore a normal response to seasonal and year-round indoor and outdoor allergens. PreHistin® is available without prescription for both long-term and daily use.

For PreHistin® product information and ordering please visit at www.PreHistin.com or call toll free 1-877-4POLLEN. For additional company information please visit the corporate website at www.Cobalis.com CONTACT:Chas Radovich, PresidentCobalis Corp.949-260-0123info@cobalis.com
'/>"/>

SOURCE Cobalis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cobalis Corp. Provides Marketing Update Conference Call for Investors
2. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
3. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
4. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
5. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
6. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
7. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
8. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
9. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
10. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
11. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... to revolutionize the emergency ambulance transport experience for the millions of people who ... Uber has disrupted the taxi industry through the use of technology. Now, SmartEMS ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, ... the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where ... city’s history as home to some of the world’s leading providers of cereal and ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
Breaking Medicine News(10 mins):